Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2023-02-16 00:00:00 ET · period of report 2023-02-14 · accession 0001104659-23-022971 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-16 | 2023-02-14 | MLYS | HBM Healthcare Investments (Cayman) Ltd. | 10% | C - Cnv Deriv | — | +2.91M | 1.94M | New | — |
| D | 2023-02-16 | 2023-02-14 | MLYS | HBM Healthcare Investments (Cayman) Ltd. | 10% | P - Purchase | $16.00 | +312.5K | 3.22M | +11% | +$5.00M |
| DM | 2023-02-16 | 2023-02-14 | MLYS | HBM Healthcare Investments (Cayman) Ltd. | 10% | C - Cnv Deriv | $0.00 | -31.37M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-14 | C | A | 964,238 | — | 2,905,606 | D | — | — | (F2) Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. |
| 2 | Common | Common Stock | 2023-02-14 | C | A | 1,941,368 | — | 1,941,368 | D | — | — | (F1) Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. |
| 3 | Common | Common Stock | 2023-02-14 | P | A | 312,500 | $16.00 | 3,218,106 | D | — | — | |
| 4 | Derivative | Series B Preferred Stock | 2023-02-14 | C | D | 10,411,846 | $0.00 | 0 | D | — · — to — | 964,238 Common Stock | (F2) Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. |
| 5 | Derivative | Series A Preferred Stock | 2023-02-14 | C | D | 20,962,895 | $0.00 | 0 | D | — · — to — | 1,941,368 Common Stock | (F1) Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. |